newsfilter
← Latest News
GlobeNewswire·

Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

–Announced prioritization of clinical programs to focus on late-stage development of oral difelikefalin for notalgia paresthetica (NP)– –Completed enrollment of KOURAGE 1 Part A portion of NP pivotal program ahead of